Your AMH Is Low. Your Genes May Explain Why.

MTHFR is the enzyme that converts folate into methylfolate, the active form your cells use to methylate DNA. Methylation is the chemical process that silences or activates genes during embryo development. It also controls how DNA packages itself inside the egg. When MTHFR works normally, your eggs methylate correctly as they develop, which reduces the risk of chromosomal nondisjunction (the error that causes miscarriage) and ensures proper gene expression as the embryo develops.

The MTHFR C677T variant, carried by roughly 40% of people of European ancestry, reduces enzyme efficiency by 40-70%. If you carry two copies of the 677T allele, your cells are producing methylfolate at a fraction of the normal rate, which means your eggs develop in a methylation-depleted state. This increases the risk of aneuploidy (wrong number of chromosomes) and miscarriage, especially in women over 35 where egg quality is already declining.

In practical terms, this means your eggs are more likely to have chromosome errors, leading to failed fertilization, early miscarriage, or aneuploid pregnancies. Your low AMH might partly reflect the fact that your body is culling eggs that don’t methylate correctly. If you’re trying to conceive naturally or through IVF, methylation status directly affects which eggs are viable and which aren’t.

The FSH receptor sits on the surface of follicle cells and listens for signals from FSH (follicle-stimulating hormone) in your bloodstream. When FSH binds to this receptor, it tells the follicle to grow, develop, and eventually release a mature egg. The strength of this signal determines how many follicles respond and how quickly they mature. A responsive FSH receptor means your ovaries can grow many follicles in a single cycle. A weakly responsive receptor means fewer follicles grow, and they grow more slowly.

The FSHR N680S variant (rs6166), present in roughly 10-15% of women, changes how efficiently FSH can activate the receptor. Women with the S/S genotype have a less responsive FSH receptor, which means their ovaries produce fewer follicles in response to the same FSH dose and their antral follicle count and AMH tend to be lower. This is especially relevant for IVF, where you rely on FSH stimulation to recruit multiple follicles in one cycle.

In practice, if you have the S/S variant, standard IVF protocols may under-stimulate you. You might start FSH, see fewer follicles recruit than expected, and end up with fewer eggs despite higher hormone levels. Your naturally lower AMH may partly reflect the fact that your follicles are less sensitive to FSH signals. The good news is that this is actionable: you just need higher doses or longer stimulation to get the same response.

Estrogen receptors sit inside cells throughout your reproductive tract, especially in the endometrium (uterine lining). When estrogen binds to these receptors, it triggers a cascade of changes: the endometrium thickens, becomes vascularized, and develops the specialized structures that allow an embryo to implant. The sensitivity of your estrogen receptors determines how much endometrial development you get from a given amount of circulating estrogen, and critically, whether your endometrium becomes receptive at the right time in your cycle.

The ESR1 variants (PvuII and XbaI), present in roughly 40% of the population, affect how efficiently estrogen receptors function. Certain variant combinations reduce endometrial receptor sensitivity, which means your endometrium may not thicken adequately or may not become receptive at the optimal time for implantation. This doesn’t necessarily cause infertility, but it can reduce implantation rates and increase miscarriage risk, especially in the context of low egg quality from other genetic factors.

You might not notice this directly in your AMH or ovarian function, but it becomes relevant in IVF outcomes. You might produce reasonable eggs, but have lower implantation rates. Or you might become pregnant but miscarry because the endometrium wasn’t optimally receptive. Some clinics now screen for ESR1 variants and adjust progesterone dosing or timing to support implantation when receptivity variants are present.

COMT is the enzyme that metabolizes estrogen, dopamine, and norepinephrine. It breaks these molecules down so your liver can excrete them. If COMT works efficiently, estrogen is cleared from your bloodstream as it should be. If COMT is slow, estrogen accumulates. Elevated estrogen creates a pro-inflammatory state in the ovaries and endometrium, increases endometriosis risk, and can paradoxically suppress ovarian response despite high hormone levels.

The COMT Val158Met variant, present in roughly 25% of people of European ancestry in the homozygous slow form, reduces enzyme activity. If you carry the Met/Met genotype, your body clears estrogen slowly, leading to elevated circulating estrogen and a pro-inflammatory ovarian environment. This is especially problematic because it doesn’t show up as an abnormality on standard hormone tests. Your estradiol might read “normal,” but your tissues are experiencing chronically elevated estrogen because it’s not being cleared.

Over time, slow COMT metabolism can worsen endometriosis, increase PCOS-like symptoms, and suppress ovarian response. Your low AMH might reflect this chronic inflammation and suppression of the ovarian reserve. Additionally, slow COMT impairs dopamine clearance, which can lead to elevated prolactin and further suppress fertility.

The vitamin D receptor (VDR) is a switch that determines how your cells respond to vitamin D. Vitamin D is not just for bone health; it’s a master regulator of immune tolerance and inflammation. In the ovaries and endometrium, vitamin D signaling is critical for proper immune balance. If VDR signaling is weak, your immune system can become overactive against reproductive tissues, increasing inflammation, endometriosis risk, and reducing implantation rates. Additionally, vitamin D deficiency is strongly associated with low AMH and reduced ovarian reserve.

The VDR FokI variant (f/F polymorphism), present in many women, affects how efficiently vitamin D activates the receptor. The ff genotype produces a longer VDR protein that is less efficient at activating vitamin D response elements, meaning you need higher vitamin D levels to achieve the same biological effect. If you carry the ff genotype and have low-normal vitamin D levels, your reproductive immune system may be under-regulated, leading to chronic low-grade inflammation in the ovaries.

In practical terms, low vitamin D combined with a VDR variant increases inflammation, worsens endometriosis or autoimmune-mediated inflammation, and is strongly associated with reduced AMH. Women with VDR variants and low AMH often have underlying inflammation driving the decline in ovarian reserve. Correcting this is foundational to any fertility protocol.

FMR1 is the gene responsible for fragile X syndrome. Most people have 5-44 CGG repeats in this gene, which is normal. But roughly 1 in 250 women carry a premutation: 55-200 CGG repeats. This premutation doesn’t cause fragile X syndrome in carriers, but it is associated with premature ovarian insufficiency (POI), also called premature menopause. Women with FMR1 premutations have elevated FSH and reduced AMH earlier than expected, sometimes in their 30s or even late 20s.

If you carry an FMR1 premutation (55-200 repeats), your risk of premature ovarian insufficiency is significantly elevated, with studies showing that roughly 20% of premutation carriers develop POI before age 40. The mechanism isn’t fully understood, but the repeats appear to interfere with normal mitochondrial function in oocytes (eggs), leading to accelerated follicle depletion. If you have low AMH and an FMR1 premutation, this is a critical finding because it tells you that your ovarian reserve is expected to decline faster than average.

You might feel like your fertility is racing against the clock. If you’re considering egg freezing or IVF, knowing your FMR1 status is essential for timing. If you carry a premutation and are not yet infertile, aggressive egg preservation and ovarian reserve optimization become higher priorities. Any children you have will need genetic counseling, because the CGG repeat can expand through generations.